Post-Activity Test and Activity Evaluation POST TEST Question Title * 1. Which of the following pathogens is most likely to be associated with late HABP (>5 days) versus early HABP? S. pneumoniae H. influenzae A. baumannii Methicillin-susceptible S. aureus Question Title * 2. Which of the following antimicrobials would be preferred for treatment of HABP caused by KPC-producing E. coli? Cefepime Piperacillin-tazobactam Ceftazidime-avibactam Amikacin plus colistin Question Title * 3. Risk factors for a multidrug-resistant Gram-negative infection include all of the following except: Recent hospitalization BMI >25 kg/m2 Prior antimicrobial use Immunosuppression Question Title * 4. A 48-year-old who was admitted to the hospital and intubated 5 days ago following a motor vehicle accident is diagnosed with HABP. A rapid diagnostic test on a BAL sample reveals ESBL-producing K. pneumoniae. What do you do next? Wait for culture and susceptibility results before initiating therapy Initiate therapy with piperacillin-tazobactam Initiate therapy with meropenem Initiate therapy with cefiderocol Question Title * 5. A 57-year-old man with a history of COPD is hospitalized due to a severe exacerbation and requires mechanical ventilation. He was previously hospitalized 6 weeks ago for a COPD exacerbation and was successfully treated with piperacillin-tazobactam. After 3 days during this current hospitalization, his condition worsens as he develops fever and increased sputum production. His WBC is 18,000/mm3 and is initiated empiric therapy with piperacillin-tazobactam. After 48 hours, he shows little improvement and culture and susceptibility results from an endotracheal aspirate sample reveal carbapenem-resistant K. pneumoniae. The next best course of action is to: Continue with the current therapy for an additional 48 hours Switch to ceftazidime-avibactam Add delafloxacin to the current regimen Add colistin to the current regimen Question Title * 6. Which of the following newer antimicrobials exhibits in vitro activity against metallo-beta-lactamases? Ceftazidime-avibactam Meropenem-vaborbactam Cefiderocol Delafloxacin Question Title * 7. A 71-year-old woman in the ICU develops VABP that is suspected to be caused by P. aeruginosa. The unit-specific antibiogram reveals high levels of resistance to piperacillin-tazobactam, ceftazidime, aztreonam, fluoroquinolones, and meropenem. Which of the following would be the least appropriate treatment option for this infection suspected to be caused by difficult-to-treat P. aeruginosa? Ceftolozane-tazobactam Ceftazidime-avibactam Meropenem-vaborbactam Imipenem-cilastatin-relebactam Question Title * 8. A 64-year-old woman who has been intubated for 7 days is diagnosed with VABP and initiated empiric therapy with vancomycin and meropenem while an endotracheal aspirate sample is submitted for culture and susceptibility testing. After 72 hours, her vital signs improve and culture results reveal ESBL-producing E. coli. The next best course of action is to: Continue with the current regimen Discontinue vancomycin only Switch from meropenem to imipenem-cilastatin-relebactam Discontinue vancomycin; switch from meropenem to eravacycline Next